This proposal describes a 5-year training program for developing an academic career in medicine and endocrinology. The principal investigator has completed his fellowship training in endocrinology at UCSD, and now will expand his scientific skills by pursuing postdoctoral training in Dr. Ronald M. Evans laboratory at the Salk Institute. This proposal focuses on biochemical, molecular and cellular aspects of atherogenesis, especially as it relates to signaling by nuclear hormone receptors, PPAR?, PPAR? and LXRs. We have previously identified the scavenger receptor CD36, LXR? and the reverse cholesterol transporter ABCA1 as either direct or indirect PPAR? target genes. Through these target genes PPAR? has the potential to both promote (CD36) and inhibit (LXR?/ABCA1) atherogenesis. The goal of Specific Aim 1 is to investigate whether the anti-atherogenic effects of TZDs are dependent upon PPAR? expression in lesion macrophages. Currently, it is simply unknown whether the TZDs principle action is in peripheral tissues or the lesion. Additional studies outlined in Specific Aim 2 will determine whether the LXR regulated cholesterol efflux pathway is critical to the anti-atherogenic actions of TZDs.
In Specific Aim 3, we will use PPAR? null ES cells to unequivocally establish the role of this receptor in macrophage lipid metabolism and atherosclerosis. Transplantation of bone marrow from genetically engineered mice into LDLR -/- mice will allow us to specifically evaluate the role of these receptors in macrophages and atherosclerosis. This will be performed in collaboration with Dr. Linda K. Curtiss of the Scripps Research Institute, a pioneer in the field of bone marrow transplantation and atherosclerosis. Collectively, these studies will provide insights into the transcriptional control of atherogenesis, and potentially lead to the identification of new therapeutic targets to treat this chronic disease. Dr. Evans' laboratory at the Salk Institute, Dr. Curtiss's laboratory at the Scripps Research Institute and UCSD provide an ideal setting for my training as a physician-scientist. This setting combines the strengths of both basic science and clinical research in nuclear receptors and vascular disease, and thus will be an extremely fertile environment for my development as a principal investigator.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
7K08DK062386-02
Application #
6696812
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2002-09-15
Project End
2007-06-30
Budget Start
2002-09-30
Budget End
2003-06-30
Support Year
2
Fiscal Year
2002
Total Cost
$128,087
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Chawla, Ajay (2010) Control of macrophage activation and function by PPARs. Circ Res 106:1559-69
Dunn, Shannon E; Bhat, Roopa; Straus, Daniel S et al. (2010) Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med 207:1599-608
Mukundan, Lata; Odegaard, Justin I; Morel, Christine R et al. (2009) PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med 15:1266-72
Odegaard, Justin I; Chawla, Ajay (2008) Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 4:619-26
Odegaard, Justin I; Ricardo-Gonzalez, Roberto R; Goforth, Matthew H et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116-20
Odegaard, Justin I; Vats, Divya; Zhang, Lina et al. (2007) Quantitative expansion of ES cell-derived myeloid progenitors capable of differentiating into macrophages. J Leukoc Biol 81:711-9
Vats, Divya; Mukundan, Lata; Odegaard, Justin I et al. (2006) Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab 4:13-24